195 related articles for article (PubMed ID: 20950435)
1. Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma.
Garcia I; Mayol G; Rodríguez E; Suñol M; Gershon TR; Ríos J; Cheung NK; Kieran MW; George RE; Perez-Atayde AR; Casala C; Galván P; de Torres C; Mora J; Lavarino C
Mol Cancer; 2010 Oct; 9():277. PubMed ID: 20950435
[TBL] [Abstract][Full Text] [Related]
2. Retinoic acid-induced CHD5 upregulation and neuronal differentiation of neuroblastoma.
Higashi M; Kolla V; Iyer R; Naraparaju K; Zhuang T; Kolla S; Brodeur GM
Mol Cancer; 2015 Aug; 14():150. PubMed ID: 26245651
[TBL] [Abstract][Full Text] [Related]
3. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas.
Fujita T; Igarashi J; Okawa ER; Gotoh T; Manne J; Kolla V; Kim J; Zhao H; Pawel BR; London WB; Maris JM; White PS; Brodeur GM
J Natl Cancer Inst; 2008 Jul; 100(13):940-9. PubMed ID: 18577749
[TBL] [Abstract][Full Text] [Related]
4. Decreased expression of chromodomain helicase DNA-binding protein 5 is an unfavorable prognostic marker in patients with primary gallbladder carcinoma.
Du X; Wu T; Lu J; Zang L; Song N; Yang T; Zhao H; Wang S
Clin Transl Oncol; 2013 Mar; 15(3):198-204. PubMed ID: 22855185
[TBL] [Abstract][Full Text] [Related]
5. Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer.
Wu X; Zhu Z; Li W; Fu X; Su D; Fu L; Zhang Z; Luo A; Sun X; Fu L; Dong JT
Breast Cancer Res; 2012 May; 14(3):R73. PubMed ID: 22569290
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of CHD5 Inactivation in neuroblastomas.
Koyama H; Zhuang T; Light JE; Kolla V; Higashi M; McGrady PW; London WB; Brodeur GM
Clin Cancer Res; 2012 Mar; 18(6):1588-97. PubMed ID: 22294723
[TBL] [Abstract][Full Text] [Related]
7. Role of microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene in neuroblastomas.
Naraparaju K; Kolla V; Zhuang T; Higashi M; Iyer R; Kolla S; Okawa ER; Blobel GA; Brodeur GM
Oncotarget; 2016 Mar; 7(13):15977-85. PubMed ID: 26895110
[TBL] [Abstract][Full Text] [Related]
8. The involvement of CHD5 hypermethylation in laryngeal squamous cell carcinoma.
Wang J; Chen H; Fu S; Xu ZM; Sun KL; Fu WN
Oral Oncol; 2011 Jul; 47(7):601-8. PubMed ID: 21636313
[TBL] [Abstract][Full Text] [Related]
9. The chromatin remodeling factor CHD5 is a transcriptional repressor of WEE1.
Quan J; Adelmant G; Marto JA; Look AT; Yusufzai T
PLoS One; 2014; 9(9):e108066. PubMed ID: 25247294
[TBL] [Abstract][Full Text] [Related]
10. CHD5 Downregulation Associated with Poor Prognosis in Epithelial Ovarian Cancer.
Wong RR; Chan LK; Tsang TP; Lee CW; Cheung TH; Yim SF; Siu NS; Lee SN; Yu MY; Chim SS; Wong YF; Chung TK
Gynecol Obstet Invest; 2011; 72(3):203-7. PubMed ID: 21860208
[TBL] [Abstract][Full Text] [Related]
11. Role of CHD5 in human cancers: 10 years later.
Kolla V; Zhuang T; Higashi M; Naraparaju K; Brodeur GM
Cancer Res; 2014 Feb; 74(3):652-8. PubMed ID: 24419087
[TBL] [Abstract][Full Text] [Related]
12. CHD5 is down-regulated through promoter hypermethylation in gastric cancer.
Wang X; Lau KK; So LK; Lam YW
J Biomed Sci; 2009 Oct; 16(1):95. PubMed ID: 19840376
[TBL] [Abstract][Full Text] [Related]
13. Genistein demethylates the promoter of CHD5 and inhibits neuroblastoma growth in vivo.
Li H; Xu W; Huang Y; Huang X; Xu L; Lv Z
Int J Mol Med; 2012 Nov; 30(5):1081-6. PubMed ID: 22960751
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5.
Cai C; Ashktorab H; Pang X; Zhao Y; Sha W; Liu Y; Gu X
PLoS One; 2012; 7(1):e29750. PubMed ID: 22235338
[TBL] [Abstract][Full Text] [Related]
15. Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer.
Hall WA; Petrova AV; Colbert LE; Hardy CW; Fisher SB; Saka B; Shelton JW; Warren MD; Pantazides BG; Gandhi K; Kowalski J; Kooby DA; El-Rayes BF; Staley CA; Volkan Adsay N; Curran WJ; Landry JC; Maithel SK; Yu DS
Oncogene; 2014 Nov; 33(47):5450-6. PubMed ID: 24276239
[TBL] [Abstract][Full Text] [Related]
16. CHD5 a tumour suppressor is epigenetically silenced in hepatocellular carcinoma.
Zhao R; Wang N; Huang H; Ma W; Yan Q
Liver Int; 2014 Jul; 34(6):e151-60. PubMed ID: 24529164
[TBL] [Abstract][Full Text] [Related]
17. Chromodomain Helicase DNA-Binding Protein 5 Inhibits Renal Cell Carcinoma Tumorigenesis by Activation of the p53 and RB Pathways.
Huang S; Yan Q; Xiong S; Peng Y; Zhao R; Liu C
Biomed Res Int; 2020; 2020():5425612. PubMed ID: 33062682
[TBL] [Abstract][Full Text] [Related]
18. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system.
Thompson PM; Gotoh T; Kok M; White PS; Brodeur GM
Oncogene; 2003 Feb; 22(7):1002-11. PubMed ID: 12592387
[TBL] [Abstract][Full Text] [Related]
19. Pan-Cancer Analysis Identifies CHD5 as a Potential Biomarker for Glioma.
Xu L; Shao F; Luo T; Li Q; Tan D; Tan Y
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955624
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of chromatin remodeling factor CHD5 is associated with a poor prognosis in human glioma.
Wang L; He S; Tu Y; Ji P; Zong J; Zhang J; Feng F; Zhao J; Gao G; Zhang Y
J Clin Neurosci; 2013 Jul; 20(7):958-63. PubMed ID: 23707602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
